Skip to main content
    P

    Pulse Biosciences Inc (PLSE)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $45.59
    -0.73 (-1.58%)

    Market Cap: $3.46B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(13/30)
    Avg Surprise
    -2.79%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.29
    Range$-0.30 - $-0.28
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.28-0.9%
    60d ago$-0.29+2.5%
    30d ago$-0.29+2.5%
    7d ago$-0.290.0%
    Current$-0.29
    Revenue Consensus
    $526000
    Range$400000 - $600000
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.32
    Range$-0.34 - $-0.30
    4 analysts
    Revenue Consensus
    $562670
    Range$140670 - $790670
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.32---
    Sep 26EST
    		-$-0.29---
    Jun 26
    Reported Aug 6
    		$-0.36$-0.31-16.13%Miss-28.6%
    Mar 26
    Reported May 4
    		$-0.24$-0.22-9.73%Miss+3.5%
    Dec 25
    Reported Feb 19
    		$-0.18$-0.21+14.29%Beat+42.4%
    Sep 25
    Reported Nov 5
    		$-0.29$-0.31+6.45%Beat-39.7%
    Jun 25
    Reported Aug 12
    		$-0.28$-0.26-7.69%Miss-40.6%
    Mar 25
    Reported May 8
    		$-0.25N/AN/ABeat-39.0%
    Dec 24
    Reported Mar 27
    		$-0.31$-0.24-30.17%Miss-44.2%
    Sep 24
    Reported Oct 30
    		$-0.21$-0.24+13.50%Beat-9.3%
    Jun 24
    Reported Aug 12
    		$-0.20$-0.20+0.45%Beat+9.5%
    Mar 24
    Reported May 7
    		$-0.18$-0.24+25.00%Beat+30.8%
    Dec 23
    Reported Mar 28
    		$-0.22$-0.24+9.71%Beat+13.3%
    Sep 23
    Reported Nov 13
    		$-0.19$-0.22+13.64%Beat+61.2%
    Jun 23
    Reported Aug 10
    		$-0.22$-0.24+8.33%Beat+50.0%
    Mar 23
    Reported May 11
    		$-0.26$-0.22-18.18%Miss+55.2%
    Dec 22
    Reported Mar 30
    		$-0.25$-0.24-4.17%Miss+51.9%
    Sep 22
    Reported Nov 10
    		$-0.49$-0.45-8.89%Miss-2.1%
    Jun 22
    Reported Aug 10
    		$-0.44$-0.40-10.00%Miss+8.3%
    Mar 22
    Reported May 11
    		$-0.58$-0.52-11.54%Miss-31.8%
    Dec 21
    Reported Mar 31
    		$-0.52$-0.51-1.96%Miss+3.7%
    Sep 21
    Reported Nov 15
    		$-0.48$-0.53+9.43%Beat+5.9%
    Jun 21
    Reported Aug 9
    		$-0.48$-0.52+7.69%Beat+9.4%
    Mar 21
    Reported May 10
    		$-0.44$-0.49+10.20%Beat+22.8%
    Dec 20
    Reported Feb 22
    		$-0.54$-0.45-20.00%Miss+18.2%
    Sep 20
    Reported Nov 9
    		$-0.51$-0.44-15.91%Miss+10.5%
    Jun 20
    Reported Aug 10
    		$-0.53$-0.50-6.00%Miss+3.6%
    Mar 20
    Reported May 11
    		$-0.57$-0.47-21.28%Miss-16.3%
    Dec 19
    Reported Mar 16
    		$-0.66$-0.61-8.20%Miss-29.4%
    Sep 19
    Reported Nov 7
    		$-0.57$-0.61+6.56%Beat+10.9%
    Jun 19
    Reported Aug 8
    		$-0.55$-0.51-7.84%Miss-1.9%
    Mar 19
    Reported Apr 30
    		$-0.49$-0.44-11.36%Miss+3.9%
    Dec 18
    Reported Mar 14
    		$-0.51$-0.51+0.00%Beat+1.9%
    Sep 18
    Reported Oct 30
    		$-0.64N/AN/ABeat-23.1%
    Jun 18
    Reported Jul 31
    		$-0.54N/AN/ABeat-25.6%
    Mar 18
    Reported May 8
    		$-0.51N/AN/ABeat-121.7%
    Dec 17
    Reported Mar 16
    		$-0.52N/AN/ABeat-146.4%
    Sep 17
    Reported Nov 7
    		$-0.52N/AN/ABeat-
    Jun 17
    Reported Jul 27
    		$-0.43N/AN/ABeat-
    Mar 17
    Reported May 4
    		$-0.23N/AN/ABeat-
    Dec 16
    Reported Mar 14
    		$-0.21N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-42.55EV/EBITDAN/A
    Price/FCF-51.39xFCF Yield-1.95%
    Profitability
    Profit Margin0.00%Operating Margin-5823.00%
    ROE-78.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio9.63xQuick Ratio9.61x
    Trading Statistics
    Beta1.57Avg Volume512.79K
    52-Week High$58.9052-Week Low$12.56

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$49.39
    SMA 20$50.61
    SMA 50$49.48
    SMA 200$29.30
    EMA 10$49.09
    EMA 20$49.82
    EMA 50$47.29
    EMA 200$33.34

    MACD

    Line: -0.37Signal: 0.37Hist: -0.74

    ADX

    ADX: 21.1+DI: 14.2-DI: 22.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$53.80

    Bollinger Bands

    Upper Band$55.27
    Lower Band$45.95
    %B Position1841%(Upper)
    Band Width-0.04

    RSI (14-Day)

    Neutral
    40.3

    Momentum Oscillators

    Stoch %K17.0
    Stoch %D31.3
    Williams %R-83.7
    ROC (10d)-8.5%
    Momentum-4.24
    CCI (20d)-194.9
    MFI (14d)39.0

    Volatility Measures

    ATR (14d)$3.47(7.6%)
    StdDev (20d)2.33
    Hist Vol57.6%(High)

    Volume Flow

    VWAP$45.41
    OBV10.5M
    AD Line-319.2K
    CMF (20d)-0.125

    Volume Metrics

    Avg Vol (20d)483.6K
    Vol Ratio0.9x
    VWMA (20d)$50.74

    Pivot Points

    R3$52.76
    R2$50.87
    R1$48.59
    Pivot Point$46.70
    S1$44.42
    S2$42.53
    S3$40.25

    Advanced Oscillators

    TSI-3.31
    Ultimate Osc51.5
    KST-20.99

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$434,000$401,000$264,000$86,000$0$0$1.66M$0$0$0$1.74M$0
    Cost of Revenue$273,000$370,000$260,000$279,000$0$0$832,000$0$0$0$304,000$0
    Gross Profit$161,000$31,000$4,000$-193,000$0$0$832,000$0$0$0$1.44M$0
    Operating Expenses$25.43M$19.18M$18.26M$20.17M$20.27M$18.04M$20.26M$13.65M$11.73M$10.62M$12.53M$11.25M
    R&D$16.98M$12.59M$10.93M$11.39M$12.09M$10.31M$10.66M$7.70M$7.23M$6.74M$7.80M$7.47M
    SG&A$8.46M$6.59M$7.33M$8.78M$8.19M$7.73M$9.60M$5.95M$4.50M$3.87M$4.73M$3.78M
    Operating Income$-25,272,000$-19,150,000$-18,253,000$-20,367,000$-20,275,000$-18,044,000$-20,261,000$-13,655,000$-11,726,000$-10,615,000$-12,533,000$-11,252,000
    Interest Income$600,000$593,000$853,000$1.00M$1.13M$1.25M$893,000$976,000$343,000$478,000$600,000$686,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-24,657,000$-18,581,000$-17,433,000$-19,385,000$-19,168,000$-16,795,000$-19,385,000$-12,680,000$-11,383,000$-10,137,000$-11,933,000$-10,566,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-24,657,000$-18,581,000$-17,433,000$-19,385,000$-19,168,000$-16,795,000$-19,385,000$-12,680,000$-11,383,000$-10,137,000$-11,933,000$-10,566,000
    EBITDA$-25,003,000$-18,919,000$-17,994,000$-20,686,000$-20,298,000$-17,493,000$-19,974,000$-13,362,000$-11,428,000$-10,316,000$-12,229,000$-10,953,000
    EBIT$-25,257,000$-19,174,000$-18,253,000$-20,386,000$-20,297,000$-18,050,000$-20,261,000$-13,656,000$-11,726,000$-10,615,000$-12,533,000$-11,252,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PLSE

    News

    Oppenheimer lifts target for Pulse Biosciences stock to USD 60.00

    Oppenheimer has raised its price target for Pulse Biosciences (PLSE) stock to $60.00, up from $35.00, while maintaining an Outperform rating. Mizuho also increased its target to $55.00. The company's stock was trading at...

    ad-hoc-news.de•10/15/26•Bullish

    Oppenheimer maintains Outperform rating on Pulse Biosciences, $60 price target

    Oppenheimer has reiterated its Outperform rating on Pulse Biosciences (PLSE), setting a price target of $60, indicating a potential upside of 14.4% from its previous closing price. This positive outlook is driven by...

    TradingView•10/13/26•Bullish

    Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Pulse Biosciences has granted equity awards to two new employees under Nasdaq Listing Rule 5635(c)(4) as inducement for their employment. The awards consist of options to purchase up to 5,700 shares of common stock...

    FinancialContent•10/9/26•Somewhat-Bullish

    Pulse Biosciences (NasdaqCM:PLSE) Stock Price

    Pulse Biosciences (PLSE) stock is currently valued at US$53.81, with a fair value of US$54.00, suggesting it is fairly valued. The company recently completed patient enrollment for its pivotal NANOPULSE-AF trial for its...

    Simply Wall Street•10/8/26•Somewhat-Bullish

    Pulse Biosciences stock reaches 164 patient study target

    Pulse Biosciences (PLSE) has reached its 164-patient enrollment target in its pivotal atrial fibrillation study for the NANOPULSE-AF IDE...

    AD HOC NEWS•10/7/26•Bullish

    PLSE Valuation and Fair Value

    P/E
    -42.6x
    P/FCF
    -51.4x
    PEG
    0.0x
    P/B
    31.7x
    See GNG's fair value

    PLSE Profitability: Margins, ROIC and FCF

    Gross margin
    0.3%
    Operating margin
    -5823.0%
    Net margin
    0.0%
    ROE
    -78.5%
    FCF margin
    -5180.4%
    FCF yield
    -1.9%

    PLSE Competitors

    CompanyTicker
    Legend Biotech CorpLEGN
    Cidara Therapeutics IncCDTX
    Veracyte IncVCYT
    Viking Therapeutics IncVKTX
    iRhythm Technologies IncIRTC
    CareDx IncCDNA
    Organon & CoOGN
    Tarsus Pharmaceuticals IncTARS

    Sector: Healthcare

    PLSE Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PLSE Bull Case vs Bear Case

    Bull case

    • 100.0% of PLSE's analyst ratings are Buy or Strong Buy.

    PLSE Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -3.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.29
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About PLSE

    Does PLSE pay dividends?

    Pulse Biosciences Inc (PLSE) does not currently pay a regular dividend.

    What is PLSE's market cap?

    Pulse Biosciences Inc (PLSE) has a market capitalization of $3.46B with a current stock price of $45.59.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In